Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
- First Posted Date
- 2006-05-08
- Last Posted Date
- 2011-02-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 216
- Registration Number
- NCT00322621
- Locations
- 🇮🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy
Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2009-09-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 89
- Registration Number
- NCT00320515
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan
Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2012-01-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 524
- Registration Number
- NCT00320489
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taoyuan City, Taiwan
A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2013-07-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 187
- Registration Number
- NCT00320541
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico
Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- Interventions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2010-01-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 269
- Registration Number
- NCT00320528
- Locations
- 🇮🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Viterbo, Italy
Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer
- First Posted Date
- 2006-04-20
- Last Posted Date
- 2009-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 60
- Registration Number
- NCT00316199
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China
A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia
- Conditions
- First Posted Date
- 2006-04-20
- Last Posted Date
- 2007-06-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 160
- Registration Number
- NCT00316238
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yamagata, Japan
Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen
- Conditions
- Interventions
- First Posted Date
- 2006-04-20
- Last Posted Date
- 2010-07-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 31
- Registration Number
- NCT00316225
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain
Observational Study of Pergolide Mesylate and Cardiac Valvulopathy
- Conditions
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2007-07-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT00311532
- Locations
- 🇮🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parma, Italy
An Open Label Study of Oral Enzastaurin in Participants With Cancer
- First Posted Date
- 2006-03-31
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 23
- Registration Number
- NCT00309140
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sun City, Arizona, United States